Pharmacological targeting of the hepcidin/ferroportin axis

Frontiers in Pharmacology

Volumn 7, Issue JUN, 2016, Pages

  Sebastiani, Giada ^a,b   Wilkinson, Nicole ^c   Pantopoulos, Kostas ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Anemia; Erythropoiesis; Hemochromatosis; Inflammation; Iron metabolism

Indexed keywords

FERROPORTIN; HEPCIDIN; INTERLEUKIN 6; STAT3 PROTEIN;

ANEMIA; ANEMIA OF CHRONIC DISEASE; CHRONIC DISEASE; DISEASE ASSOCIATION; ERYTHROBLAST; ERYTHROPOIESIS; HEMOCHROMATOSIS; HEREDITARY HEMOCHROMATOSIS; HUMAN; IRON ABSORPTION; IRON DEFICIENCY ANEMIA; IRON OVERLOAD; IRON STORAGE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN TARGETING; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84977633506     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2016.00160     Document Type: Review

References (96)

1. Akinc, A., Chan-Daniels, A., Sehgal, A., Foster, D., Bettencourt, B. R., Hettinger, J., et al. (2011). "Targeting the hepcidin pathway with RNAi therapeutics for the treatment of Anemia, "in 53th Annual Meeting of the American Society for Hematology (ASH) (San Diego, CA), Abstract 688.
2. Arezes, J., Jung, G., Gabayan, V., Valore, E., Ruchala, P., Gulig, P. A., et al. (2015). Hepcidin-induced hypoferremia is a critical host defense mechanism against the siderophilic bacterium Vibrio vulnificus. Cell Host Microbe 17, 47-57. doi: 10.1016/j.chom.2014.12.001
3. Arlet, J. B., Hermine, O., Darnige, L., Ostland, V., Westerman, M., Badoual, C., et al. (2010). Iron-deficiency anemia in Castleman disease: implication of the interleukin 6/hepcidin pathway. Pediatrics 126, e1608-e1612. doi: 10.1542/peds.2010-1123
4. Asperti, M., Naggi, A., Esposito, E., Ruzzenenti, P., Di Somma, M., Gryzik, M., et al. (2016). High sulfation and a high molecular weight are important for anti-hepcidin activity of heparin. Front. Pharmacol. 6:316. doi: 10.3389/fphar.2015.00316
5. Babitt, J. L., Huang, F. W., Wrighting, D. M., Xia, Y., Sidis, Y., Samad, T. A., et al. (2006). Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat. Genet. 38, 531-539. doi: 10.1038/ng1777
6. Bacchetta, J., Zaritsky, J. J., Sea, J. L., Chun, R. F., Lisse, T. S., Zavala, K., et al. (2014). Suppression of iron-regulatory hepcidin by vitamin D. J. Am. Soc. Nephrol. 25, 564-572. doi: 10.1681/ASN.2013040355
7. Blanchette, N. L., Manz, D. H., Torti, F. M., and Torti, S. V. (2016). Modulation of hepcidin to treat iron deregulation: potential clinical applications. Expert Rev. Hematol. 9, 169-186. doi: 10.1586/17474086.2016.1124757
8. Boergermann, J. H., Kopf, J., Yu, P. B., and Knaus, P. (2010). Dorsomorphin and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells. Int. J. Biochem. Cell Biol. 42, 1802-1807. doi: 10.1016/j.biocel.2010.07.018
9. Böser, P., Seemann, D., Liguori, M. J., Fan, L., Huang, L., Hafner, M., et al. (2015). Anti-repulsive guidance molecule C (RGMc) antibodies increases serum iron in rats and cynomolgus monkeys by hepcidin downregulation. AAPS J. 17, 930-938. doi: 10.1208/s12248-015-9770-4
10. Camaschella, C., and Nai, A. (2016). Ineffective erythropoiesis and regulation of iron status in iron loading anaemias. Br. J. Haematol. 172, 512-523. doi: 10.1111/bjh.13820
11. Casper, C., Chaturvedi, S., Munshi, N., Wong, R., Qi, M., Schaffer, M., et al. (2015). Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (Anti-IL6 Monoclonal Antibody) in patients with multicentric castleman disease. Clin. Cancer Res. 21, 4294-4304. doi: 10.1158/1078-0432.CCR-15-0134
12. Casu, C., Oikonomidou, P. R., Chen, H., Nandi, V., Ginzburg, Y., Prasad, P., et al. (2016). Minihepcidin peptides as disease modifiers in mice affected by beta-thalassemia and polycythemia vera. Blood. doi: 10.1182/blood-2015-10-676742. [Epub ahead of print].
13. Cheng, C. J., Tietjen, G. T., Saucier-Sawyer, J. K., and Saltzman, W. M. (2015). A holistic approach to targeting disease with polymeric nanoparticles. Nat. Rev. Drug Discov. 14, 239-247. doi: 10.1038/nrd4503
14. Chua, K., Fung, E., Micewicz, E. D., Ganz, T., Nemeth, E., and Ruchala, P. (2015). Small cyclic agonists of iron regulatory hormone hepcidin. Bioorg. Med. Chem. Lett. 25, 4961-4969. doi: 10.1016/j.bmcl.2015.03.012
15. Cooke, K. S., Hinkle, B., Salimi-Moosavi, H., Foltz, I., King, C., Rathanaswami, P., et al. (2013). A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. Blood 122, 3054-3061. doi: 10.1182/blood-2013-06-505792
16. Corradini, E., Schmidt, P. J., Meynard, D., Garuti, C., Montosi, G., Chen, S., et al. (2010). BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice. Gastroenterology 139, 1721-1729. doi: 10.1053/j.gastro.2010.07.044
17. Doyle, M. K., Rahman, M. U., Frederick, B., Birbara, C. A., De Vries, D., Toedter, G., et al. (2013). Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial. Rheumatology 52, 1214-1219. doi: 10.1093/rheumatology/kes381
18. Drakesmith, H., Nemeth, E., and Ganz, T. (2015). Ironing out Ferroportin. Cell Metab. 22, 777-787. doi: 10.1016/j.cmet.2015.09.006
19. Fatih, N., Camberlein, E., Island, M. L., Corlu, A., Abgueguen, E., Detivaud, L., et al. (2010). Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form. J. Mol. Med. 88, 477-486. doi: 10.1007/s00109-009-0588-3
20. Finberg, K. E., Whittlesey, R. L., and Andrews, N. C. (2011). Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice. Blood 117, 4590-4599. doi: 10.1182/blood-2010-10-315507
21. Frank, K. M., Schneewind, O., and Shieh, W. J. (2011). Investigation of a researcher's death due to septicemic plague. N. Engl. J. Med. 364, 2563-2564. doi: 10.1056/NEJMc1010939
22. Fung, E., Sugianto, P., Hsu, J., Damoiseaux, R., Ganz, T., and Nemeth, E. (2013). High-throughput screening of small molecules identifies hepcidin antagonists. Mol. Pharmacol. 83, 681-690. doi: 10.1124/mol.112.083428
23. Ganz, T. (2013). Systemic iron homeostasis. Physiol. Rev. 93, 1721-1741. doi: 10.1152/physrev.00008.2013
24. Ganz, T., and Nemeth, E. (2015). Iron homeostasis in host defence and inflammation. Nat. Rev. Immunol. 15, 500-510. doi: 10.1038/nri3863
25. Gardenghi, S., Ramos, P., Marongiu, M. F., Melchiori, L., Breda, L., Guy, E., et al. (2010). Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemic mice. J. Clin. Invest. 120, 4466-4477. doi: 10.1172/JCI41717
26. Gaun, V., Patchen, B., Volovetz, J., Zhen, A. W., Andreev, A., Pollastri, M. P., et al. (2014). A chemical screen identifies small molecules that regulate hepcidin expression. Blood Cells Mol. Dis. 53, 231-240. doi: 10.1016/j.bcmd.2014.06.002
27. Ginzburg, Y., and Rivella, S. (2011). beta-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood 118, 4321-4330. doi: 10.1182/blood-2011-03-283614
28. Gkouvatsos, K., Papanikolaou, G., and Pantopoulos, K. (2012). Regulation of iron transport and the role of transferrin. Biochim. Biophys. Acta 1820, 188-202. doi: 10.1016/j.bbagen.2011.10.013
29. Guida, C., Altamura, S., Klein, F. A., Galy, B., Boutros, M., Ulmer, A. J., et al. (2015). A novel inflammatory pathway mediating rapid hepcidin-independent hypoferremia. Blood 125, 2265-2275. doi: 10.1182/blood-2014-08-595256
30. Guo, S., Casu, C., Gardenghi, S., Booten, S., Aghajan, M., Peralta, R., et al. (2013a). Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice. J. Clin. Invest. 123, 1531-1541. doi: 10.1172/JCI66969
31. Guo, W., Bachman, E., Li, M., Roy, C. N., Blusztajn, J., Wong, S., et al. (2013b). Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells. Aging Cell 12, 280-291. doi: 10.1111/acel.12052
32. Hashizume, M., Uchiyama, Y., Horai, N., Tomosugi, N., and Mihara, M. (2010). Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production. Rheumatol. Int. 30, 917-923. doi: 10.1007/s00296-009-1075-4
33. Heeney, M. M., and Finberg, K. E. (2014). Iron-Refractory Iron Deficiency Anemia (IRIDA). Hematol. Oncol. Clin. North Am. 28, 637-652. doi: 10.1016/j.hoc.2014.04.009
34. Hohlbaum, A. M., Trentman, S., Gille, H., Allesdorfer, A., Belaiba, R. S., Huelsmeyer, M., et al. (2011). "Discovery and preclinical characterization of a novel hepcidin antagonist with tunable PK/PD properties for the treatment of anemia in different patient populations, "in 53th Annual Meeting of the American Society for Hematology (ASH) (San Diego, CA), Abstract 687.
35. Isaacs, J. D., Harari, O., Kobold, U., Lee, J. S., and Bernasconi, C. (2013). Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Res. Ther. 15, R204. doi: 10.1186/ar4397
36. Jiao, Y., Wilkinson, J. T., Di, X., Wang, W., Hatcher, H., Kock, N. D., et al. (2009). Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood 113, 462-469. doi: 10.1182/blood-2008-05-155952
37. Kim, A., and Nemeth, E. (2015). New insights into iron regulation and erythropoiesis. Curr. Opin. Hematol. 22, 199-205. doi: 10.1097/MOH.0000000000000132
38. Kovac, S., Boser, P., Cui, Y., Ferring-Appel, D., Casarrubea, D., Huang, L., et al. (2016). Anti-hemojuvelin antibody corrects anemia caused by inappropriately high hepcidin levels. Haematologica 101, e173. doi: 10.3324/haematol.2015.140772
39. Lakhal-Littleton, S., Wolna, M., Carr, C. A., Miller, J. J., Christian, H. C., Ball, V., et al. (2015). Cardiac ferroportin regulates cellular iron homeostasis and is important for cardiac function. Proc. Natl. Acad. Sci. U.S.A. 112, 3164-3169. doi: 10.1073/pnas.1422373112
40. Latour, C., Kautz, L., Besson-Fournier, C., Island, M. L., Canonne-Hergaux, F., Loreal, O., et al. (2014). Testosterone perturbs systemic iron balance through activation of epidermal growth factor receptor signaling in the liver and repression of hepcidin. Hepatology 59, 683-694. doi: 10.1002/hep.26648
41. Li, X., Rhee, D. K., Malhotra, R., Mayeur, C., Hurst, L. A., Ager, E., et al. (2016). Progesterone receptor membrane component-1 regulates hepcidin biosynthesis. J. Clin. Invest. 126, 389-401. doi: 10.1172/JCI83831
42. Lin, L., Goldberg, Y. P., and Ganz, T. (2005). Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood 106, 2884-2889. doi: 10.1182/blood-2005-05-1845
43. Liu, J., Sun, B., Yin, H., and Liu, S. (2016). Hepcidin: a promising therapeutic target for iron disorders: a systematic review. Medicine 95, e3150. doi: 10.1097/MD.0000000000003150
44. Ludwiczek, S., Aigner, E., Theurl, I., and Weiss, G. (2003). Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 101, 4148-4154. doi: 10.1182/blood-2002-08-2459
45. Mayeur, C., Kolodziej, S. A., Wang, A., Xu, X., Lee, A., Yu, P. B., et al. (2015). Oral administration of a bone morphogenetic protein type I receptor inhibitor prevents the development of anemia of inflammation. Haematologica 100, e68-e71. doi: 10.3324/haematol.2014.111484
46. Mayr, R., Janecke, A. R., Schranz, M., Griffiths, W. J., Vogel, W., Pietrangelo, A., et al. (2010). Ferroportin disease: a systematic meta-analysis of clinical and molecular findings. J. Hepatol. 53, 941-949. doi: 10.1016/j.jhep.2010.05.016
47. Merle, U., Fein, E., Gehrke, S. G., Stremmel, W., and Kulaksiz, H. (2007). The iron regulatory peptide hepcidin is expressed in the heart and regulated by hypoxia and inflammation. Endocrinology 148, 2663-2668. doi: 10.1210/en.2006-1331
48. Mleczko-Sanecka, K., Roche, F., Da Silva, A. R., Call, D., D'Alessio, F., Ragab, A., et al. (2014). Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras/RAF and nutrient-dependent mTOR signaling. Blood 123, 1574-1585. doi: 10.1182/blood-2013-07-515957
49. Moebius, U., Feuerer, W., Fenzl, E., Van Swelm, R., Swinkels, D. W., and Hohlbaum, A. (2015). "A phase I study investigating the safety, tolerability, pharmacokinetics and pharmacodynamic activity of the hepcidin antagonist PRS-080#022. Results from a randomized, placebo controlled, double-blind study following single administration to healthy subjects, "in 57th Annual Meeting of the American Society for Hematology (ASH) (Orlando, FL), Abstract 536.
50. Nai, A., Pagani, A., Mandelli, G., Lidonnici, M. R., Silvestri, L., Ferrari, G., et al. (2012). Deletion of TMPRSS6 attenuates the phenotype in a mouse model of beta-thalassemia. Blood 119, 5021-5029. doi: 10.1182/blood-2012-01-401885
51. Nai, A., Rubio, A., Campanella, A., Gourbeyre, O., Artuso, I., Bordini, J., et al. (2016). Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice. Blood 127, 2327-2336. doi: 10.1182/blood-2015-11-681494
52. Nicolas, G., Viatte, L., Lou, D. Q., Bennoun, M., Beaumont, C., Kahn, A., et al. (2003). Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat. Genet. 34, 97-101. doi: 10.1038/ng1150
53. Papanikolaou, G., and Pantopoulos, K. (2005). Iron metabolism and toxicity. Toxicol. Appl. Pharmacol. 202, 199-211. doi: 10.1016/j.taap.2004.06.021
54. Perlstein, T. S., Pande, R., Berliner, N., and Vanasse, G. J. (2011). Prevalence of 25-hydroxyvitamin D deficiency in subgroups of elderly persons with anemia: association with anemia of inflammation. Blood 117, 2800-2806. doi: 10.1182/blood-2010-09-309708
55. Peterson, P. A., Soh, K. K., Lee, Y. S., Kim, W., Whatcott, C. J., Siddiqui-Jain, A., et al. (2015). "ALK2 Inhibition via TP-0184 abrogates inflammation-induced hepcidin expression and is a potential therapeutic for anemia of chronic disease, "in 57th Annual Meeting of the American Society for Hematology (ASH), (Orlando, FL), Abstract 273.
56. Pietrangelo, A. (2015). Genetics, genetic testing, and management of hemochromatosis: 15 years since hepcidin. Gastroenterology 149, 1240-1251. doi: 10.1053/j.gastro.2015.06.045
57. Pietrangelo, A. (2016). Iron and the liver. Liver Int. 36(Suppl. 1), 116-123. doi: 10.1111/liv.13020
58. Pinnix, Z. K., Miller, L. D., Wang, W., D'agostino, R. Jr., Kute, T., Willingham, M. C., et al. (2010). Ferroportin and iron regulation in breast cancer progression and prognosis. Sci. Transl. Med. 2, 43ra56. doi: 10.1126/scitranslmed.3001127
59. Poli, M., Asperti, M., Naggi, A., Campostrini, N., Girelli, D., Corbella, M., et al. (2014a). Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo. Blood 123, 1564-1573. doi: 10.1182/blood-2013-07-515221
60. Poli, M., Asperti, M., Ruzzenenti, P., Mandelli, L., Campostrini, N., Martini, G., et al. (2014b). Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo. Biochem. Pharmacol. 92, 467-475. doi: 10.1016/j.bcp.2014.09.007
61. Poli, M., Asperti, M., Ruzzenenti, P., Regoni, M., and Arosio, P. (2014c). Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Front. Pharmacol. 5:86. doi: 10.3389/fphar.2014.00086
62. Poli, M., Girelli, D., Campostrini, N., Maccarinelli, F., Finazzi, D., Luscieti, S., et al. (2011). Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo. Blood 117, 997-1004. doi: 10.1182/blood-2010-06-289082
63. Portugal, S., Carret, C., Recker, M., Armitage, A. E., Goncalves, L. A., Epiphanio, S., et al. (2011). Host-mediated regulation of superinfection in malaria. Nat. Med. 17, 732-737. doi: 10.1038/nm.2368
64. Powell, L. W., Seckington, R. C., and Deugnier, Y. (2016). Haemochromatosis. Lancet. doi: 10.1016/S0140-6736(15)01315-X. [Epub ahead of print].
65. Preza, G. C., Ruchala, P., Pinon, R., Ramos, E., Qiao, B., Peralta, M. A., et al. (2011). Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. J. Clin. Invest. 121, 4880-4888. doi: 10.1172/JCI57693
66. Ramos, E., Ruchala, P., Goodnough, J. B., Kautz, L., Preza, G. C., Nemeth, E., et al. (2012). Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood 120, 3829-3836. doi: 10.1182/blood-2012-07-440743
67. Rochette, L., Gudjoncik, A., Guenancia, C., Zeller, M., Cottin, Y., and Vergely, C. (2015). The iron-regulatory hormone hepcidin: a possible therapeutic target? Pharmacol. Ther. 146, 35-52. doi: 10.1016/j.pharmthera.2014.09.004
68. Ruchala, P., and Nemeth, E. (2014). The pathophysiology and pharmacology of hepcidin. Trends Pharmacol. Sci. 35, 155-161. doi: 10.1016/j.tips.2014.01.004
69. Saeed, O., Otsuka, F., Polavarapu, R., Karmali, V., Weiss, D., Davis, T., et al. (2012). Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 32, 299-307. doi: 10.1161/ATVBAHA.111.240101
70. Sasu, B. J., Cooke, K. S., Arvedson, T. L., Plewa, C., Ellison, A. R., Sheng, J., et al. (2010). Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 115, 3616-3624. doi: 10.1182/blood-2009-09-245977
71. Schmidt, P. J., and Fleming, M. D. (2014). Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches. Hematol. Oncol. Clin. North Am. 28, 387-401. doi: 10.1016/j.hoc.2013.11.004
72. Schmidt, P. J., Toudjarska, I., Sendamarai, A. K., Racie, T., Milstein, S., Bettencourt, B. R., et al. (2013). An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine beta-thalassemia intermedia. Blood 121, 1200-1208. doi: 10.1182/blood-2012-09-453977
73. Schwoebel, F., Van Eijk, L. T., Zboralski, D., Sell, S., Buchner, K., Maasch, C., et al. (2013). The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood 121, 2311-2315. doi: 10.1182/blood-2012-09-456756
74. Sebastiani, G., and Pantopoulos, K. (2011). Disorders associated with systemic or local iron overload: from pathophysiology to clinical practice. Metallomics 3, 971-986. doi: 10.1039/c1mt00082a
75. Sehgal, A., Vaishnaw, A., and Fitzgerald, K. (2013). Liver as a target for oligonucleotide therapeutics. J. Hepatol. 59, 1354-1359. doi: 10.1016/j.jhep.2013.05.045
76. Sivakumar, M., and Powell, L. W. (2016). Management of human factors engineering-associated hemochromatosis: a 2015 update. World J. Hepatol. 8, 395-400. doi: 10.4254/wjh.v8.i8.395
77. Song, S. N., Iwahashi, M., Tomosugi, N., Uno, K., Yamana, J., Yamana, S., et al. (2013). Comparative evaluation of the effects of treatment with tocilizumab and TNF-alpha inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. Arthritis Res. Ther. 15, R141. doi: 10.1186/ar4323
78. Song, S. N., Tomosugi, N., Kawabata, H., Ishikawa, T., Nishikawa, T., and Yoshizaki, K. (2010). Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 116, 3627-3634. doi: 10.1182/blood-2010-03-271791
79. Steinbicker, A. U., Sachidanandan, C., Vonner, A. J., Yusuf, R. Z., Deng, D. Y., Lai, C. S., et al. (2011). Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood 117, 4915-4923. doi: 10.1182/blood-2010-10-313064
80. Sun, C. C., Vaja, V., Chen, S., Theurl, I., Stepanek, A., Brown, D. E., et al. (2013). A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. Nephrol. Dial. Transplant. 28, 1733-1743. doi: 10.1093/ndt/gfs584
81. Tesfay, L., Clausen, K. A., Kim, J. W., Hegde, P., Wang, X., Miller, L. D., et al. (2015). Hepcidin regulation in prostate and its disruption in prostate cancer. Cancer Res. 75, 2254-2263. doi: 10.1158/0008-5472.CAN-14-2465
82. Theurl, I., Schroll, A., Sonnweber, T., Nairz, M., Theurl, M., Willenbacher, W., et al. (2011). Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood 118, 4977-4984. doi: 10.1182/blood-2011-03-345066
83. Tsuchiya, K., and Nitta, K. (2013). Hepcidin is a potential regulator of iron status in chronic kidney disease. Ther. Apher. Dial. 17, 1-8. doi: 10.1111/1744-9987.12001
84. Urrutia, P., Aguirre, P., Esparza, A., Tapia, V., Mena, N. P., Arredondo, M., et al. (2013). Inflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cells. J. Neurochem. 126, 541-549. doi: 10.1111/jnc.12244
85. Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Ytiu, R. V., et al. (2015). "Phase 1 study of a hepcidin antagonist, LY2787106, in cancer-associated anemia, "in 57th Annual Meeting of the American Society for Hematology (ASH) (Orlando, FL), Abstract 537.
86. Van Eijk, L. T., John, A. S., Schwoebel, F., Summo, L., Vauleon, S., Zollner, S., et al. (2014). Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood 124, 2643-2646. doi: 10.1182/blood-2014-03-559484
87. Wang, C. Y., and Babitt, J. L. (2016). Hepcidin regulation in the anemia of inflammation. Curr. Opin. Hematol. 23, 189-197. doi: 10.1097/MOH.0000000000000236
88. Weiss, G. (2015). Anemia of chronic disorders: new diagnostic tools and new treatment strategies. Semin. Hematol. 52, 313-320. doi: 10.1053/j.seminhematol.2015.07.004
89. Witcher, D. R., Leung, D., Hill, K. A., De Rosa, D. C., Xu, J., Manetta, J., et al. (2013). "LY2928057, an antibody targeting ferroportin, is a potent inhibitor of hepcidin activity and increases iron mobilization in normal cynomolgus monkeys, "in 55th Annual Meeting of the American Society for Hematology (ASH) (New Orleans, LA), Abstract 3433.
90. Yang, Q., Jian, J., Katz, S., Abramson, S. B., and Huang, X. (2012). 17beta-Estradiol inhibits iron hormone hepcidin through an estrogen responsive element half-site. Endocrinology 153, 3170-3178. doi: 10.1210/en.2011-2045
91. Yu, P. B., Hong, C. C., Sachidanandan, C., Babitt, J. L., Deng, D. Y., Hoyng, S. A., et al. (2008). Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat. Chem. Biol. 4, 33-41. doi: 10.1038/nchembio.2007.54
92. Zeng, C., Chen, Q., Zhang, K., Chen, Q., Song, S., and Fang, X. (2015). Hepatic hepcidin protects against polymicrobial sepsis in mice by regulating host iron status. Anesthesiology 122, 374-386. doi: 10.1097/ALN.0000000000000466
93. Zhang, S. P., Wang, Z., Wang, L. X., and Liu, S. J. (2011). AG490: an inhibitor of hepcidin expression in vivo. World J. Gastroenterol. 17, 5032-5034. doi: 10.3748/wjg.v17.i45.5032
94. Zhen, A. W., Nguyen, N. H., Gibert, Y., Motola, S., Buckett, P., Wessling-Resnick, M., et al. (2013). The small molecule, genistein, increases hepcidin expression in human hepatocytes. Hepatology 58, 1315-1325. doi: 10.1002/hep.26490
95. Zopf, S., Kremer, A. E., Neurath, M. F., and Siebler, J. (2016). Advances in hepatitis C therapy: what is the current state-what come's next? World J. Hepatol. 8, 139-147. doi: 10.4254/wjh.v8.i3.139
96. Zughaier, S. M., Alvarez, J. A., Sloan, J. H., Konrad, R. J., and Tangpricha, V. (2014). The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes. J. Clin. Transl. Endocrinol. 1, 19-25. doi: 10.1016/j.jcte.2014.01.003